目的:探讨抗CD20单抗联合化疗治疗侵袭性B细胞非霍奇金淋巴瘤( B-NHL)的临床疗效。方法将40例侵袭性B-NHL患者随机分为观察组和对照组,每组20例,对照组采用CHOP方案化疗,观察组在对照组的基础上加用抗CD20单克隆抗体利妥昔治疗,比较两组的疗效及不良反应。结果观察组治疗后完全缓解13例,部分缓解3例,总有效率为80.0%(16/20),显著高于对照组40.0%(8/20),P<0.05。不良反应发热例数观察组显著多于对照组,P<0.05。其他不良反应两组无显著性差异,P>0.05。结论抗CD20单抗联合化疗治疗侵袭性B-NHL有较好的近期疗效,不良反应可耐受,有利于改善患者的生存质量。
Objective To study the clinical efficacy of anti-CD20 monoclonal antibody combined with chemotherapy for aggressive B cell non-Hodgkin's lymphoma ( B-NHL) .Methods 40 cases of aggressive B-NHL were randomly divided into the observation group(n=20) and the control group(n=20).The control group were treated with CHOP chemotherapy,and the ob-servation group received anti-CD20 monoclonal antibody rituximab on the basis of the control group,the efficacy and toxicity of the 2 groups were compared.Results After treatment in the observation group,complete remission was 13 cases,partial remission was 3 cases,the total effective rate was 80.0% (16/20),which was significantly higher than that of the control group 40.0%(8/20),P<0.05.Fever cases in the observation group were significantly less than those of the control group,P<0.05.Other ad-verse reactions of the 2 groups had no significant difference,P>0.05.Conclusion Anti-CD20 monoclonal antibody combined with chemotherapy for aggressive B-NHL has good short-term effects with tolerable adverse reactions,it helps to improve the quali-ty of life of patients.